Prostate Gland Cancer Testing Urgently Needed, Says Former Prime Minister Sunak
Ex-government leader Rishi Sunak has intensified his call for a focused testing initiative for prostate gland cancer.
During a recently conducted interview, he stated being "convinced of the critical importance" of introducing such a programme that would be cost-effective, achievable and "protect numerous lives".
These remarks come as the UK National Screening Committee reviews its decision from the previous five-year period not to recommend regular testing.
Journalistic accounts propose the body may continue with its current stance.
Olympic Champion Adds Voice to Movement
Olympic cycling champion Sir Hoy, who has advanced prostate gland cancer, supports younger men to be tested.
He suggests reducing the age threshold for requesting a PSA blood screening.
At present, it is not standard practice to healthy individuals who are below fifty.
The prostate-specific antigen screening remains controversial though. Measurements can increase for causes apart from cancer, such as infections, resulting in false positives.
Skeptics maintain this can lead to unnecessary treatment and side effects.
Focused Screening Proposal
The recommended testing initiative would focus on males between 45 and 69 with a hereditary background of prostate gland cancer and black men, who face increased susceptibility.
This group encompasses around 1.3 million individuals males in the Britain.
Research projections propose the initiative would require £25m per year - or about £18 per participant - similar to intestinal and breast testing.
The estimate involves twenty percent of suitable candidates would be contacted yearly, with a nearly three-quarters participation level.
Clinical procedures (scans and biopsies) would need to increase by almost a quarter, with only a reasonable increase in medical workforce, according to the report.
Clinical Community Reaction
Various clinical specialists are doubtful about the effectiveness of testing.
They assert there is still a possibility that individuals will be medically managed for the disease when it is potentially overtreated and will then have to live with complications such as incontinence and erectile dysfunction.
One respected urology professional remarked that "The challenge is we can often detect conditions that may not require to be addressed and we risk inflicting harm...and my worry at the moment is that risk to reward balance requires refinement."
Patient Perspectives
Patient voices are also affecting the conversation.
A particular example concerns a sixty-six year old who, after seeking a prostate screening, was diagnosed with the condition at the age of fifty-nine and was told it had metastasized to his pelvic area.
He has since experienced chemo treatment, radiation treatment and endocrine treatment but is not curable.
The man endorses testing for those who are genetically predisposed.
"That is essential to me because of my boys – they are 38 and 40 – I want them tested as soon as possible. If I had been tested at 50 I am sure I wouldn't be in the circumstances I am now," he said.
Next Steps
The Screening Advisory Body will have to weigh up the data and perspectives.
While the new report indicates the consequences for staffing and accessibility of a testing initiative would be manageable, others have contended that it would divert scanning capacity otherwise allocated to individuals being treated for alternative medical problems.
The current debate highlights the complicated balance between timely diagnosis and likely excessive intervention in prostate cancer management.
